Innocan Pharma Corp. Aktie
4,64 €
Deine Einschätzung
Innocan Pharma Corp. Aktie
Was spricht für und gegen Innocan Pharma Corp. in den nächsten Jahren?
Pro
Kontra
News
Innocan Pharma Corporation plant Listing an der NYSE American Stock Exchange mit gleichzeitigem Emissionsangebot
Herzliya, Israel und Calgary, AB - 2. Januar 2026 / IRW-Press / Innocan Pharma Corporation (CSE: INNO) (FWB: IP4) (OTCQB: INNPF) (das „Unternehmen“ oder „Innocan“), ein pharmazeutisches
Innocan Pharma Corporation Anticipates Listing on the NYSE American Stock Exchange with Concurrent Offering
Herzliya, Israel and Calgary, AB – 2 January 2026– Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing
Innocan Pharma Reports Financial Results for Q3 2025, with Revenues at US $21.6M
Herzliya, Israel and Calgary, Alberta – November 27, 2025 – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the “Company” or “Innocan”), a pharmaceutical technology company

